Chronic kidney disease
Autor: | Paola Romagnani, Giuseppe Remuzzi, Richard Glassock, Adeera Levin, Kitty J. Jager, Marcello Tonelli, Ziad Massy, Christoph Wanner, Hans-Joachim Anders |
---|---|
Přispěvatelé: | ACS - Amsterdam Cardiovascular Sciences, APH - Aging & Later Life, APH - Quality of Care, Medical Informatics, APH - Global Health, ACS - Pulmonary hypertension & thrombosis |
Rok vydání: | 2017 |
Předmět: |
Medicine (all)
030232 urology & nephrology General Medicine Nephrons 030204 cardiovascular system & hematology Kidney urologic and male genital diseases Fibrosis Kidney Transplantation 3. Good health Diabetes Complications 03 medical and health sciences 0302 clinical medicine Cardiovascular Diseases Risk Factors Hypertension Prevalence Humans Renal Insufficiency Chronic |
Zdroj: | Nature Reviews Disease Primers Nature reviews. Disease primers, 3:17088. Nature Publishing Group |
ISSN: | 2056-676X |
DOI: | 10.1038/nrdp.2017.88 |
Popis: | Chronic kidney disease (CKD) is defined by persistent urine abnormalities, structural abnormalities or impaired excretory renal function suggestive of a loss of functional nephrons. The majority of patients with CKD are at risk of accelerated cardiovascular disease and death. For those who progress to end-stage renal disease, the limited accessibility to renal replacement therapy is a problem in many parts of the world. Risk factors for the development and progression of CKD include low nephron number at birth, nephron loss due to increasing age and acute or chronic kidney injuries caused by toxic exposures or diseases (for example, obesity and type 2 diabetes mellitus). The management of patients with CKD is focused on early detection or prevention, treatment of the underlying cause (if possible) to curb progression and attention to secondary processes that contribute to ongoing nephron loss. Blood pressure control, inhibition of the renin-angiotensin system and disease-specific interventions are the cornerstones of therapy. CKD complications such as anaemia, metabolic acidosis and secondary hyperparathyroidism affect cardiovascular health and quality of life, and require diagnosis and treatment. |
Databáze: | OpenAIRE |
Externí odkaz: |